Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Antonio Costanzo, Giovanni Pellacani et al.|Frontiers in Medicine|2023Cited by 55
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 Pandemic: Risk analysis from the PSO-BIO-COVID observational studyMarina Talamonti, Luca Bianchi, Angelo Valerio Marzano et al.|Expert Opinion on Biological Therapy|2020Cited by 43
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)Diego Orsini, Antonio Costanzo, Giovanni Pellacani et al.|Dermatology Practical & Conceptual|2024Cited by 34
Management of biological therapies for chronic plaque psoriasis during COVID‐19 emergency in ItalyMarina Talamonti, Gabriella Fabbrocini, Andrea Conti et al.|Journal of the European Academy of Dermatology and Venereology|2020Cited by 32
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)Luigi Gargiulo, Alessandra Narcisi, Diego Orsini et al.|Journal of Dermatological Treatment|2024Cited by 21